On this website for something called "Bite Back" magazine a group identifying itself as MFAH Austria is claiming responsibility for the recent attacks on Swiss drugmaker Novartis and its employees, including CEO Dr. Daniel Vasella.
Stocks ended flat Tuesday as investors took a breather after Monday's blockbuster rally. Bank and airline stocks were bright spots, while investors sold tech, materials and energy. Pending-home sales jumped 3.6 percent in June, beating expectations. It was the fifth straight monthly gain and the longest such streak in six years. Read and listen to what the pros had to say...
Reports surfaced this morning that animal rights activists are suspected of setting fire to and badly damaging the vacation home of Novartis CEO Daniel Vasella in the wee hours of the morning yesterday.
The drug companies help pay my salary. Not directly, of course (although I bet there are conspiracy theorists out there who are probably convinced they do), but they undoubtedly contribute a sizeable amount of advertising dollars to the company I work for.
Investors are placing their bets ahead of a string of pharma earnings due both this week and next. What must you know?
Earnings season should provide a fresh view of the U.S. economy and may shake the stock market out of its summer doldrums.
As the Markey-Waxman bill on carbon emissions cap-and-trade makes it way through the Senate, a new carbon-counting reality may soon be here for American businesses.
As flu season goes into high gear in the southern hemisphere, the U.S. Dept. of Homeland Security is preparing for a potential flu outbreak in the United States, according to its top official.
Analysts are busy jawboning this morning about the side effect Amgen revealed cropped up in a large, late-stage study of its bone drug known as D-mab for breast cancer patients whose disease has spread to the bones.
After hours shares of Amgen popped as much as 12%. What drove the stock that much higher?
Both the S&P and Dow rose on Wednesday, the start of the third quarter, as reassuring manufacturing data reinforced hopes that the world's economy is on the road to recovery.
ACC, ADA, AHA, ASCO, ICAD, TCT. That's just a handful of the acronyms and abbreviations for scientific and medical conferences that I've attended over the years. But this year I might be able to add RITA to my dance card. I'd never heard of her (it) before this morning when I got this press release from Crucell, which owns technology for faster, better, cheaper vaccine manufacturing.
Following are the day’s biggest winners and losers. Find out why shares of Alcoa and Evergreen Solar popped while Apple and Morgan Stanley dropped.
I've got new competition. Sort of. GlaxoSmithKline sent me an email this morning calling my attention to its new external blog, "American Health: More Than Medicine." A pretty long name for a blog, one that screams that it went through the corporate approval wringer, but at least GSK is putting itself out there.
The World Health Organisation warned on Friday against a false sense of security from waning and apparently mild outbreaks of H1N1 flu, saying the worst may not be over.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Cramer makes the call on viewers' favorite stocks.
Stocks turned lower on Thursday as bank stocks backed off their early rally. Fed Reserve Chairman Bernanke said increasing the effectiveness of bank supervision is a "top priority" for the Fed. Treasury Secretary Tim Geithner sought to ease fears about the results by saying that none of the banks being tested face the risk of insolvency. (UPDATED: Stress test results released.)
Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.
Stocks turned lower on Thursday as bank stocks backed off their early rally. Fed Reserve Chairman Bernanke said increasing the effectiveness of bank supervision is a "top priority" for the Fed. Treasury Secretary Tim Geithner sought to ease fears about the results by saying that none of the banks being tested face the risk of insolvency.